v3.25.2
Income Taxes (Tables)
12 Months Ended
May 31, 2025
Dec. 31, 2024
Income Taxes [Line Items]    
Schedule of Provision for Income Taxes Expenses  

The components of the provision for Income taxes expenses are:

 

Year ended
December 31,
2024

 

Year ended
December 31,
2023

 

Year ended
December 31,
2022

Current

 

$

 

$

 

$

Deferred

 

 

 

 

 

 

Total income taxes expense

 

$

 

$

 

 

Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate  

The reconciliation of income taxes expenses computed at the Hong Kong statutory tax rate applicable to income tax expense is as follows:

 

Year ended
December 31,
2024

 

Year ended
December 31,
2023

 

Year ended
December 31,
2022

Net loss before tax

 

$

(4,157,737

)

 

$

(4,340,975

)

 

$

(11,525,102

)

Provision for income tax benefit at Hong Kong statutory income tax rate (16.5%)

 

 

(686,027

)

 

 

(716,261

)

 

 

(1,901,642

)

Impact of different tax rates in other jurisdictions

 

 

(10,814

)

 

 

(16,272

)

 

 

(263,787

)

Non-taxable income

 

 

(5,477

)

 

 

(1,071,774

)

 

 

(907,495

)

Non-deductible expenses

 

 

195

 

 

 

98,704

 

 

 

 

Change in valuation allowance

 

 

702,123

 

 

 

1,705,603

 

 

 

3,072,924

 

Effective income tax expense

 

$

 

 

$

 

 

$

 

Schedule of Deferred Tax Asset and Liabilities   The following represents the tax effect of each major type of temporary difference.
 

December 31,
2024

 

December 31,
2023

Deferred tax asset:

 

 

 

 

 

 

 

 

Tax loss carry forward

 

$

15,107,318

 

 

$

16,956,748

 

Share-based payment expenses

 

 

 

 

 

229,126

 

Depreciation and amortization

 

 

128,896

 

 

 

128,866

 

Impairment loss on assets

 

 

537,830

 

 

 

92,416

 

Total Deferred tax asset

 

 

15,774,044

 

 

 

17,407,156

 

Valuation allowance

 

 

(15,774,044

)

 

 

(17,407,156

)

Deferred tax asset, net of valuation allowance

 

$

 

 

$

 

Schedule of Changes in Valuation Allowance  

Changes in valuation allowance are as follows:

 

Year ended
December 31,
2024

 

Year ended
December 31,
2023

 

Year ended
December 31,
2022

Balance as of January 1

 

$

17,407,156

 

 

$

15,705,088

 

 

$

12,632,164

Additions

 

 

702,123

 

 

 

1,705,603

 

 

 

3,072,924

Disposal

 

 

(2,335,235

)

 

 

(3,535

)

 

 

Balance as of December 31

 

$

15,774,044

 

 

$

17,407,156

 

 

$

15,705,088

DiamiR Biosciences Corp. [Member]    
Income Taxes [Line Items]    
Schedule of Provision for Income Taxes Expenses

For the years ended May 31, 2025 and 2024, the provision for income taxes consisted of the following:

 

2025

 

2024

Current:

 

 

   

 

 

Federal

 

$

16,483

 

$

112,947

State

 

 

1,456

 

 

1,456

Total current

 

 

17,939

 

 

114,403

Deferred:

 

 

   

 

 

Federal

 

 

 

 

State

 

 

 

 

Total deferred

 

 

 

 

Total

 

$

17,939

 

$

114,403

 
Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate

For the years ended May 31, 2025 and 2024, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:

 

2025

 

2024

Income taxes at Federal statutory rate

 

21.0

%

 

21.0

%

Discounts and interest on notes

 

(2.4

)%

 

(2.1

)%

Financing costs

 

(4.3

)%

 

%

State taxes

 

%

 

(4.2

)%

Other

 

(2.3

)%

 

(1.2

)%

Change in valuation allowance

 

(14.3

)%

 

(36.3

)%

Income tax provision

 

(2.3

)%

 

(22.9

)%

 
Schedule of Deferred Tax Asset and Liabilities

The Company’s deferred tax assets and liabilities consist of the following at May 31, 2025 and 2024:

 

May 31,
2025

 

May 31,
2024

Deferred tax assets:

 

 

 

 

 

 

 

 

Tax benefit of net operating loss carry-forward (NOL)

 

$

351,453

 

 

$

247,637

 

FIN48 reduction in NOL

 

 

(269,420

)

 

 

(219,793

)

Stock compensation

 

 

351,136

 

 

 

346,030

 

Research and development expenses

 

 

422,170

 

 

 

372,544

 

Other

 

 

1,152

 

 

 

2,432

 

Total deferred tax assets:

 

 

856,490

 

 

 

748,850

 

Deferred tax liabilities

 

 

(8,152

)

 

 

(4,583

)

Net deferred tax assets:

 

 

848,338

 

 

 

744,267

 

Valuation allowance for deferred tax assets

 

 

(848,338

)

 

 

(744,267

)

Deferred tax assets, net of valuation allowance

 

$

 

 

$

 

 
Schedule of Unrecognized Tax Benefits The Company recognizes a tax benefit from an uncertain tax position when it is more-likely-than-not that it will be sustained upon examination by tax authorities.

Unrecognized tax benefits, May 31, 2023

 

$

217,239

Gross increases – tax positions in current period

 

 

155,305

Unrecognized tax benefits, May 31, 2024

 

 

372,544

Gross increases – tax positions in current period

 

 

49,626

Unrecognized tax benefits, May 31, 2025

 

$

422,170